ANIP — ANI PHARMACEUTICALS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About ANI PHARMACEUTICALS INC (ANIP)
ANI PHARMACEUTICALS INC (ANIP) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $54M. Across recent filings, tracked investors recorded 7 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in ANIP
How many top investors track ANIP
A small number of top investors own this.
ANIP Ownership Composition
How ANI PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.
- Other80.5%
- Hedge Funds19.5%
Tracked investors reporting ANIP
- Ken GriffinMar 31, 2026Citadel AdvisorsShares25MValue$31M% Portfolio0.01%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares592KValue$45.5M% Portfolio0.02%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares15MValue$18.6M% Portfolio0.02%
Recent activity
- $42.6MFeb 17, 2026
- $45.5MMay 15, 2026
- New$9.5MFeb 17, 2026
- New$31MMay 15, 2026
- New$18.6MMay 15, 2026
- New$54.3MNov 14, 2025
- New$54.3MNov 14, 2025
Frequently asked questions
- How many institutional investors hold ANIP?
- 3 tracked institutional investors disclosed a position in ANIP (ANI PHARMACEUTICALS INC) in their most recent 13F filing.
- Who is the largest institutional holder of ANIP?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in ANIP, valued at $54M.
- Did institutional ownership of ANIP increase or decrease?
- Across recent 13F filings, tracked investors recorded 7 new positions, 0 increased, 0 reduced, and 0 fully exited ANIP.
- Where does this ANIP ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.